Anti-nerve Growth Factor Monoclonal Antibodies for the Control of Pain in Dogs and Cats

摘要

In veterinary medicine, the mainstay of drug therapy for the alleviation of clinical signs associated with osteoarthritis (OA)-(or degenerative joint disease (DJD)) associated pain in dogs are the non-steroidal anti-inflammatory drugs (NSAIDs), and additionally in dogs, the recently approved PGE2 receptor blocker grapiprant. There are no other classes of drug approved by the Food and Drug Administration - Center for Veterinary Medicine (FDA-CVM) for the control of OA-associated pain in dogs. In cats,the non-steroidal anti-inflammatory drug meloxicam is approved in Europe for use in treating chronic pain in cats but has not been approved for this use in the United States. There are no other approved medications for the long-term treatment of chronic pain in the cat, despite the clear need for such a treatment.